Experimental cancer combo trial halted early
NCT ID NCT04260802
First seen Jan 10, 2026 · Last updated May 23, 2026 · Updated 18 times
Summary
This study tested a new drug called OC-001, either by itself or combined with avelumab (an immunotherapy), in people with advanced cancers that had spread. The goal was to check safety and how the drug moves through the body. The trial was stopped early, and only 73 people were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, H2X 0A9, Canada
-
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2, Canada
-
Jewish General Hospital - Clinical Research Unit
Montreal, Quebec, H3T 1E2, Canada
-
Ottawa Hospital Cancer Centre (OHRI)
Ottawa, Ontario, Canada
-
Princess Margaret Hospital
Toronto, Ontario, M5G 2C1, Canada
Conditions
Explore the condition pages connected to this study.